I know many, understandably, are in doubt as to the likelihood of a J&J deal on the ATI results. Just as a little indication of where big Pharma is going, have a look at Novartis (I am long for disclosure) R&D presentation. Its a whopper, but interesting.
The company is looking to have the majority of its revenues coming from cellular and bilogic therapies by 2030. Where are these new treatments coming from? Partnerships and acquisitions mostly.
Tenocytes and chondrocytes might be foreign words to most investors, but rest assured big Pharma well aware. Go to slide 107 and you will see the stated importance of stem-cells and chondrocytes in particular in new catilage regeneration. Even if the Aussie share market and vast swathes of the medical world are too ignorant to recognise the importance of these factors in regenrative medicine, big Pharma is not. J&J and other big Pharam will be well aware of the potential of OCC's tencoyte and chondrocyte therapies and alert to the forthcoming results.
https://www.novartis.com/sites/novartis_com/files/novartis-r-d-day-2021-presentation.pdf
J&J Partnership, page-360
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |